论文部分内容阅读
目的对比塞来昔布和布洛芬缓释胶囊治疗类风湿关节炎(RA)的临床效果。方法选取2013年3月—2016年3月在樟树市人民医院接受治疗的RA患者68例,随机分为A、B两组,每组34例。A组口服塞来昔布胶囊治疗;B组口服布洛芬缓释胶囊治疗。比较两组关节疼痛指数、关节肿胀指数、关节压痛指数、晨僵持续时间、握力、血清类风湿因子(RF)、C反应蛋白(CRP)、红细胞沉降率(ESR)以及临床效果、不良反应发生情况。结果治疗前两组患者观察指标比较,差异无统计学意义(P>0.05);治疗后,A组患者的关节疼痛指数、关节肿胀指数、关节压痛指数低于B组,晨僵持续时间短于B组,握力大于B组,血清RF、CRP和ESR均低于B组,差异有统计学意义(P<0.05)。A组治疗总有效率高于B组,不良反应发生率低于B组,差异有统计学意义(P<0.05)。结论与布洛芬缓释胶囊相比,塞来昔布在治疗RA中的疗效更高、不良反应更少,是一种安全有效的治疗药物。
Objective To compare the clinical efficacy of celecoxib and ibuprofen sustained-release capsules in the treatment of rheumatoid arthritis (RA). Methods From March 2013 to March 2016, 68 patients with RA who were treated in Zhangshu People’s Hospital were randomly divided into A and B groups, 34 in each. Group A received oral celecoxib capsules; Group B received oral sustained-release capsules Ibuprofen. The pain index, joint swelling index, joint tenderness index, duration of morning stiffness, grip strength, serum rheumatoid factor (RF), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and clinical effect were compared between the two groups. Happening. Results Before treatment, there was no significant difference between the two groups (P> 0.05). After treatment, the pain index, joint swelling index and joint tenderness index of patients in group A were lower than those in group B, and the duration of morning stiffness was shorter than In group B, the grip strength was greater than that in group B, and the levels of RF, CRP and ESR in serum were lower in group B than those in group B (P <0.05). The total effective rate of treatment in group A was higher than that in group B, and the incidence of adverse reactions was lower than that in group B, the difference was statistically significant (P <0.05). Conclusion Compared with ibuprofen sustained-release capsules, celecoxib is more effective in the treatment of RA with fewer adverse reactions and is a safe and effective therapeutic drug.